53% Of US Adults Are Eligible For Semaglutide

A total of 136.8 million adults in the U.S. are clinically eligible for semaglutide, the glucagon-like peptide-1 (GLP-1) generic for Novo Nordisk’s Ozempic, Wegovy, and Rybelsus. Based on the 2020 census results reporting 258.3 million adults in the U.S., this means that about 53% of adults are eligible for semaglutide’s indications. This number of eligible adults exceeds the eligibility for statins (about 82 million), currently the most prescribed pharmaceuticals among U.S. adults. Ozempic and Rybelsus treat diabetes, and Wegovy is for chronic weight management and cardiovascular events.

The researchers noted . . .